Noveayr Therapeutics, is a respiratory focused pharmaceutical company with an integrated development and manufacturing capability. Through its portfolio, IP and scientific expertise it is almost uniquely positioned to address respiratory disease from cause to consequence; helping eradicate one of its major causes in smoking, offering life changing treatments for asthma and COPD and addressing the environmental consequences of those treatments. It is a specialist in medicines delivered through propellant based pressurized metered dose inhalers (pMDIs). We are committed to changing over to the next generation "green" propellant capabilities with low global warming potential, through reformulating major existing products and enabling the development of new products. Noveayr’s heritage is as a contract development and manufacturer. It has a track record of developing and delivering propellant based medicines for territories including the US, EU, and International markets. In it’s GMP certified state-of-the-art facilities based in Cheshire UK, Noveayr specialises in pMDIs, with additional capability in Creams, Nasal Sprays and Small Volume Liquids. Noveyayr Thereaputics is a part of OBG Group and is proud to be helping the world to breathe